A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients

Purpose Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of treatment options facilitate personalized treatment, but they also complicate treatment decision making. Decision support systems (DSS), which provide individualized prognostic information, can overcome this but are currently lacking. A DSS for stage III NSCLC requires the development and integration of multiple models. The current study takes the first step in this process by developing and validating a model that can provide physicians with a survival probability for an individual NSCLC patient. Methods and Materials Data from 548 patients with stage III NSCLC were available to enable the development of a prediction model, using stratified Cox regression. Variables were selected by using a bootstrap procedure. Performance of the model was expressed as the c statistic, assessed internally and on 2 external data sets (n=174 and n=130). Results The final multivariate model, stratified for treatment, consisted of age, gender, World Health Organization performance status, overall treatment time, equivalent radiation dose, number of positive lymph node stations, and gross tumor volume. The bootstrapped c statistic was 0.62. The model could identify risk groups in external data sets. Nomograms were constructed to predict an individual patient’s survival probability (www.predictcancer.org). The data set can be downloaded at https://www.cancerdata.org/10.1016/j.ijrobp.2015.02.048. Conclusions The prediction model for overall survival of patients with stage III NSCLC highlights the importance of combining patient, clinical, and treatment variables. Nomograms were developed and validated. This tool could be used as a first building block for a decision support system.

[1]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[3]  P. Baas,et al.  Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. , 2013, Clinical lung cancer.

[4]  P. Lambin,et al.  The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  P. Lambin,et al.  Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. , 2012, European journal of cancer.

[6]  V. Preedy,et al.  Recursive Partitioning Analysis , 2010 .

[7]  H. Bartelink,et al.  Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. , 2000, European journal of cancer.

[8]  M. J. Solan,et al.  Prognostic factors in non-small cell lung cancer. , 2003, Seminars in surgical oncology.

[9]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[10]  Martha Sajatovic,et al.  Clinical Prediction Models , 2013 .

[11]  P. Lambin,et al.  HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[12]  E. Yorke,et al.  Involved-field radiation therapy for inoperable non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Asselain,et al.  4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. , 2006, The Lancet. Oncology.

[14]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[15]  J F Fowler,et al.  Biological Factors Influencing Optimum Fractionation in Radiation Therapy , 2001, Acta oncologica.

[16]  Maria Werner-Wasik,et al.  Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[17]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[18]  D. Mark,et al.  Clinical prediction models: are we building better mousetraps? , 2003, Journal of the American College of Cardiology.

[19]  P. Lambin,et al.  Predicting outcomes in radiation oncology—multifactorial decision support systems , 2013, Nature Reviews Clinical Oncology.

[20]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[21]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Ling,et al.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[24]  Shipeng Yu,et al.  Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[25]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[26]  Philippe Lambin,et al.  Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[28]  Philippe Lambin,et al.  Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Curran,et al.  Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. , 2005, International journal of radiation oncology, biology, physics.

[30]  W. Sause,et al.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. , 2000, International journal of radiation oncology, biology, physics.

[31]  Andrew Jackson,et al.  Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  T. Pajak,et al.  Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. , 1993, International journal of radiation oncology, biology, physics.

[33]  The Complex Relationship Between Lung Tumor Volume and Survival in Patients with Non-Small Cell Lung Cancer Treated by Definitive Radiotherapy: a Prospective, Observational Prognostic Factor Study of the Trans-Tasman Radiation Oncology Group (Trog 99.05) , 2012 .

[34]  P. Lambin,et al.  Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[35]  V. Budach,et al.  Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[37]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[38]  H. Akaike A new look at the statistical model identification , 1974 .

[39]  Tae Hyun Kim,et al.  Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. , 2014, International journal of radiation oncology, biology, physics.

[40]  R. Weichselbaum,et al.  The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. , 2014, Clinical lung cancer.

[41]  E. Yorke,et al.  Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. , 2010, International journal of radiation oncology, biology, physics.

[42]  David R. Anderson,et al.  Model Selection and Multimodel Inference , 2003 .

[43]  D. Cox Note on Grouping , 1957 .

[44]  Jing Zhao,et al.  Radiation dose effect in locally advanced non-small cell lung cancer. , 2014, Journal of thoracic disease.

[45]  Yoshinao Abe,et al.  Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. , 2006, International journal of radiation oncology, biology, physics.

[46]  P. Lambin,et al.  Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). , 2011, International journal of radiation oncology, biology, physics.

[47]  Marianne Paesmans,et al.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables , 2011, Therapeutic advances in medical oncology.